Microbial Infections

Role of Biological Response Modifiers

  • Herman Friedman
  • Thomas W. Klein
  • Hideyo Yamaguchi

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 319)

Table of contents

  1. Front Matter
    Pages i-x
  2. D. C. Morrison, M.-G. Lei, T.-Y. Chen, L. M. Flebbe, J. Halling, S. Field
    Pages 23-29
  3. Phillip J. Baker, Christopher E. Taylor, Felix S. Ekwunife
    Pages 31-38
  4. Barnet M. Sultzer, Jayant Bandekar, Raymond Castagna, Khaled Abu-Lawi
    Pages 39-48
  5. Kathryn Nixdorff, Gabriele Weber, Kerstin Kaniecki, Waltraud Ruiner, Sigrid Schell
    Pages 49-61
  6. Arthur G. Johnson, Marilyn J. Odean, Akira Hasegawa
    Pages 63-67
  7. Shigeru Abe, Megumi Ohnishi, Sadao Kimura, Masatoshi Yamazaki, Haruyuki Oshima, Denichi Mizuno et al.
    Pages 69-76
  8. Barbara J. Nelson, Miodrag Belosevic, Shawn J. Green, Jim Turpin, Carol A. Nacy
    Pages 77-88
  9. Masayasu Nakano, Kazuyasu Onozuka, Hiromi Yamasu, Wang Fu Zhong, Yasunobu Nakano
    Pages 89-95
  10. Thomas W. Klein, Yoshimasa Yamamoto, Scott Wilson, Cathy Newton, Herman Friedman
    Pages 97-104
  11. M. A. Parant, F. J. Parant, C. Le Contel, P. Lefrancier, L. Chedid
    Pages 175-184

About this book

Introduction

This volume is based on the Proceedings of the International Conference on "Microbial Infections: Role of Biological Response Modifiers" held in Tampa, FL, May 29-31, 1991. The major purpose of this conference was to bring together in one forum prominent investigators from around the world studying a variety of microbial pathogens, including bacteria, viruses, and fungi, and the effects of biological response modifiers (BRM) on the immune response to these microorganisms. BRM have been widely utilized in the area of antitumor resistance and include not only experimental tumor cell vaccines, but also biologically active substances such as cytokines, i. e. , interferons, tumor necrosis factor, and interleukins, as well as products from bacteria which influence host resistance mechanisms. It is the belief of the organizers of this Conference that it was very timely to discuss in detail BRMs as they impact on microbial infections per se. It is now widely accepted that immunocompromised individuals, including those exposed to immunosuppressive substances such as antimetabolites used for chemothera­ py of malignancies, or infectious agents, such as the human immunodeficiency virus and other viruses which depress the immune response and, in turn, affect a host so as to become highly susceptible to opportunistic microorganisms, benefit from BRM stimulation of their immune system. A wide variety of immunomodulators are now being studied in terms of treating infectious diseases, as well as malignancy and autoimmune diseases.

Keywords

autoimmune disease bacteria infection infections infectious infectious disease infectious diseases interferon virus

Editors and affiliations

  • Herman Friedman
    • 1
  • Thomas W. Klein
    • 1
  • Hideyo Yamaguchi
    • 2
  1. 1.University of South FloridaTampaUSA
  2. 2.Teikyo University School of MedicineTokyoJapan

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4615-3434-1
  • Copyright Information Springer-Verlag US 1992
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-6519-8
  • Online ISBN 978-1-4615-3434-1
  • Series Print ISSN 0065-2598
  • About this book